China Pharmaceutical Distribution Industry Report, 2019-2026
  • Apr.2020
  • Hard Copy
  • USD $3,000
  • Pages:140
  • Single User License
    (PDF Unprintable)       
  • USD $2,800
  • Code: ZLC102
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,200
  • Hard Copy + Single User License
  • USD $3,200

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmaceutical retail market reached RMB466.1 billion, rising 9.9% on an annualized basis. The robust downstream demand spurs the Chinese pharmaceutical distribution market to grow apace and be expectedly worth RMB4,225.7 billion by 2026.
Western medicine sales dominate pharmaceutical distribution in China, accounting for 72.2% in 2018; the sales in East China and Central South China seize larger shares up to 62.1% together in 2018.

A competition pattern has been developed in the country where there are national pharmaceutical distributors represented by China National Pharmaceutical Group Corporation (Sinopharm), China Resources Pharmaceutical Commercial Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group and the regional ones represented by NanJing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun, Zhejiang Int'l, Realcan Pharmaceutical, Guangxi Liuzhou Pharmaceutical Co., Ltd. and Luyan Pharma Co., Ltd.

As of end of November 2018, there had been 13,598 pharmaceutical wholesalers nationwide which competed fiercely in the scattered market. The market tends to be concentrated with the incentive policies such as the two-invoice system and volume procurement. As to earnings, China National Pharmaceutical Group Corp. still led the pack and Shanghai Pharmaceuticals Holding Co., Ltd. ascended to the second place, while China Resources Pharmaceutical Commercial Group Co., Ltd. dropped a notch and ranked third. It is worth mentioning that the commercial segment of Shenzhen Neptunus Galaxy Pharmaceutical Investment Co., Ltd. reported the revenue of RMB36,976 million in 2018 (compared with just RMB64.48 million in 1998), an upsurge of 54.33% from a year earlier, helping it rise to the sixth place among Chinese pharmaceutical wholesale enterprises.


A total of 5,671 pharmaceutical retail chain enterprises in China as of the end of 2018 were in possession of 255,467 stores; 52.2% of pharmacies had been chained, a year-on-year increase of 1.7 percentage points; pharmacies covered by medical insurance had shared 72%.

The leading drug retail chains in China mainly include Yixintang , Dashenlin , LBX Pharmacy, Yifeng Pharmacy, Sinopharm , Nepstar , Zhongyou Health, Quanyi Health, Tong Jun Ge, Jianzhijia, to name a few. In 2018, the total sales of the top 100 Chinese pharmaceutical retail enterprises posted RMB143,982.52 million as a percentage of 33.4% in the total. Sinopharm, the largest pharmaceutical retail enterprise in China, secured the sales of RMB12250.53 million in 2018, equivalent to 2.8% of the total.

Huge potentials of the pharmaceutical distribution industry has lured investors and frequent M&As occurred over the recent years. With the in-rush of capital, pharmaceutical distribution companies are heading from traditional endogenous growth (such as adding products, developing customers and opening new stores) to the extensional growth like mergers and acquisitions, and the industry is increasingly concentrated.


Highlights of the report:
20120114.gifPharmaceutical distribution industry in China (development environment, status quo, market size/structure, competitive landscape, development trends, etc.);
20120114.gifChinese pharmaceutical retail market (market size, gross margin, net profit margin, quantity, ratio of pharmacies covered by medical insurance, per customer transaction, performance comparison of leading pharmaceutical retail companies);
20120114.gif16 Chinese pharmaceutical distributors (profile, operation, revenue structure, gross margin, development strategy, etc.).

1. Overview of Pharmaceutical Distribution Industry
1.1 Definition
1.2 Industry Chain
1.3 Strength and Weakness of Pharmaceutical Chain Enterprises
1.3.1 Strength of Pharmaceutical Chain Enterprises
1.3.2 Weakness of Pharmaceutical Chain Enterprises

2. Pharmaceutical Distribution Industry in China
2.1 Development Environment
2.1.1 Policy
2.1.2 Economy
2.1.3 Medical Institution
2.1.4 Health Expenditure
2.1.5 Aging
2.1.6 Per Capita Disposable Income
2.2 Status Quo
2.3 Market Size
2.4 Market Structure
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Pharmaceutical E-commerce Becomes an Important Model
2.6.2 Capital Market Plays a Bigger Role in Integration of Enterprises
2.6.3 Favorable Policies Push up Market Concentration
2.6.4 Growing Trend towards Regionalization
2.6.5 Wholesale-retail Integration Spurs Industry Consolidation
2.6.6 Prescription Leaks Facilitate the Industry
2.6.7 Individual Pharmacies Withdraw, while Chain Pharmacies Prevail
2.6.8 The Thriving Pharmaceutical O2O

3 Chinese Drug Retail Market
3.1 Market Size
3.2 Gross Margin and Net Profit Margin
3.3 Quantity
3.3.1 Top100 Pharmacy Chains
3.3.2 Online Pharmacy
3.3.3 Independent Pharmacy
3.3.4 Proportion of Pharmacies Newly Opened and Closed
3.4 Coverage of Medical Insurance
3.5 Per Customer Transaction

4. Major Enterprises
4.1 China National Accord Medicines Corporation Ltd.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Pharmaceutical Distribution Business
4.1.6 Development Strategy
4.2 Nanjing Pharmaceutical Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Pharmaceutical Distribution Business
4.2.6 Development Strategy
4.3 Shanghai No.1 Pharmacy Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Development Strategy
4.4 China National Medicines Corporation Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5Pharmaceutical Distribution Business
4.4.6 Development Strategy
4.5 Huadong Medicine Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Pharmaceutical Distribution Business
4.5.6 Development Strategy
4.6 Cachet Pharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Pharmaceutical Distribution Business
4.6.6 Development Strategy
4.7 Jointown Pharmaceutical Group Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 Pharmaceutical Distribution Business
4.7.6 Development Strategy
4.8 Realcan Pharmaceutical Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 Pharmaceutical Distribution Business
4.8.6 Development Strategy
4.9 Shanghai Pharmaceuticals Holding Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 Pharmaceutical Distribution Business
4.9.6 Development Strategy
4.10 Zhejiang Int'l Group Co., Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Pharmaceutical Distribution Business
4.10.6 Development Strategy
4.11 Zhejiang Zhenyuan Share Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Pharmaceutical Distribution Business
4.11.6 Development Strategy
4.12 China Meheco Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 Pharmaceutical Distribution Business
4.12.6 Development Strategy
4.13 Charmacy Pharmaceutical Co., Ltd.
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Pharmaceutical Distribution Business
4.13.6 Development Strategy
4.14 Luyan Pharma Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 Pharmaceutical Distribution Business
4.14.6 Development Strategy
4.15 China Resources Pharmaceutical Group Limited
4.15.1 Profile
4.15.2 Operation
4.15.3 Revenue Structure
4.15.4 Gross Margin
4.15.5 Pharmaceutical Distribution Business
4.15.6 Development Strategy
4.16 DaShenLin Pharmaceutical Group Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.16.3 Revenue Structure
4.16.4 Gross Margin
4.16.5 Pharmaceutical Distribution Business
4.16.6 Development Strategy
China Pharmaceutical Distribution Channel
Difference between Pure Marketing and Allocation in China’s Pharmaceutical Distribution
Policies on China's Pharmaceutical Distribution Industry, 2016-2020
China’s GDP, 2012-2019
Number of Medical and Healthcare Institutions in China, 2015-2019
Number of Hospitals in China, 2009-2019
Number of Hospitals in China by Economic Type, 2009-2019
Health Expenditure in China, 2010-2019
Health Expenditure in China, 2018-2025E
Population Aged over 65 in China, 2009-2025E
Residents’ Per-capita Disposable Income and YoY Growth in China, 2011-2019
Promotion and Implementation of the Two-Invoice Policy
Pharmaceutical Distribution Market Size and YoY Growth in China, 2006-2019
Pharmaceutical Distribution Market Size and YoY Growth in China, 2019-2026E
Pharmaceutical Distribution Sales Structure in China by Type, 2018
Pharmaceutical Distribution Sales Structure in China by Region, 2018
Pharmaceutical Distribution Revenue in China by Region, 2018
Top 20 Pharmaceutical Distribution Companies in China by Operating Revenue, 2017-2018
Revenue of Major Pharmaceutical Distribution Companies in China, 2013-2019
Net Income of Major Pharmaceutical Distribution Companies in China, 2013-2019
Pharmaceutical Distribution Revenue of Major Pharmaceutical Distribution Companies in China, 2013-2019
Total Sales of Pharmaceutical E-commerce Direct Reporting Enterprises (Which Are Recommended by the Local Competent Authority and Confirmed by the Ministry of Commerce and Then are Included in the Direct Designated Statistics) (without Certificate A) in China, 2015-2018
Capital Layout of China's Pharmaceutical Retail Industry in Recent Years
China's Tier-1 and Tier-2 Capital Investment in Pharmacies by Region
Regulatory Policies Prompt the Concentration of Retail Pharmacy Market in China, 2015-2019
Representative Pharmaceutical Distribution Enterprises in China by Regional Market
Policies for Prescription Outflow in China, 2015-2018
Top 10 Pharmacies in China by Prescription Drug Sales, 2018
BATJ’s Layout in Pharmaceutical O2O Platforms in China
Drug Retail Market Size and YoY Growth in China, 2012-2019
Drug Retail Market Size and YoY Growth in China, 2019-2026E
Average Gross Margin of Sample Pharmacies in China by Value, 2010-2019
Average Net Margin of Sample Pharmacies in China by Value, 2010-2019
Number of Drug Retail Chains in China, 2012-2018
Drug Retail Chains in China by Number of Stores, 2012-2018
Number of Independent Retail Drugstores in China, 2012-2018
Pharmaceutical Retail Chain Ratio in China, 2009-2018
Top 100 Pharmacy Chains in China by Total Revenue, 2018
Top 100 Pharmacy Chains via Direct Sales Mode in China, 2019
Top 50 Online Pharmacies in China, 2019
Top 30 Independent Pharmacies in China by Revenue, 2018
Proportion of New Pharmacies in China, 2014-2018
Enterprises Whose New Pharmacies Made up over 30% in China, 2018
Average Investment in a Pharmacy in China, 2014-2018
Proportion of Closed Pharmacies in China, 2014-2018
Enterprises Whose Closed Pharmacies Made up over 5% in China, 2018
Proportion of Pharmacies Covered by Medical Insurance in China, 2014-2018
Enterprises Owning 600 Pharmacies Covered by Medical Insurance in China, 2018
Enterprises Whose 95% Pharmacies Were Covered by Medical Insurance in China, 2018
Per Customer Transaction of Pharmacies in China, 2013-2018
Enterprises Whose Pharmacies Secured the Per Customer Transaction over RMB135 in China, 2018
Revenue and Net Income of China National Accord Medicines, 2013-2019
Revenue Breakdown of China National Accord Medicines by Business, 2015-2019
Gross Margin of China National Accord Medicines’ Main Business, 2016-2019
Number of Stores of China National Accord Medicines, as of the end of June 2019
O2O Platform Sales of China National Accord Medicines, 2019H1
Revenue and Net Income of Nanjing Pharmaceutical, 2013-2019
Revenue Breakdown of Nanjing Pharmaceutical by Business, 2015-2019
Revenue Breakdown of Nanjing Pharmaceutical by Region, 2015-2019
Gross Margin of Nanjing Pharmaceutical by Business, 2015-2019
Revenue and Net Income of Shanghai No.1 Pharmacy, 2013-2019
Revenue Breakdown of Shanghai No.1 Pharmacy by Business, 2014-2019
Revenue Structure of Shanghai No.1 Pharmacy by Business, 2014-2019
Gross Margin of Shanghai No.1 Pharmacy, 2016-2019
Gross Margin of Shanghai No.1 Pharmacy by Business, 2014-2018
Revenue and Net Income of China National Medicines, 2013-2019
Revenue Breakdown of China National Medicines by Business, 2014-2019
Revenue Structure of China National Medicines by Business, 2014-2019
Revenue Breakdown of China National Medicines by Region, 2014-2019
Revenue Structure of China National Medicines by Region, 2014-2019
Gross Margin of China National Medicines, 2014-2019
Gross Margin of China National Medicines by Business, 2014-2019
Revenue and Net Income of Huadong Medicine, 2013-2019
Revenue Breakdown of Huadong Medicine by Sector, 2014-2019
Revenue Structure of Huadong Medicine by Sector, 2014-2019
Gross Margin of Huadong Medicine by Sector, 2014-2019
Revenue and Net Income of Cachet Pharmaceutical, 2013-2019
Revenue Breakdown of Cachet Pharmaceutical by Business, 2014-2019
Revenue Structure of Cachet Pharmaceutical by Business, 2014-2019
Revenue Breakdown of Cachet Pharmaceutical by Region, 2014-2019
Revenue Structure of Cachet Pharmaceutical by Region, 2014-2019
Gross Margin of Cachet Pharmaceutical’s Pharmaceutical Wholesale Business, 2014-2019
Revenue and Net Income of Jointown Pharmaceutical Group, 2013-2019
Revenue Breakdown of Jointown Pharmaceutical Group by Business, 2014-2019
Revenue Structure of Jointown Pharmaceutical Group by Business, 2014-2019
Gross Margin of Jointown Pharmaceutical Group by Business, 2014-2019
Main Pharmaceutical Products Wholesaled by Jointown Pharmaceutical Group
Revenue and Net Income of Realcan Pharmaceutical, 2013-2019
Revenue Breakdown of Realcan Pharmaceutical by Business, 2014-2019
Revenue Structure of Realcan Pharmaceutical by Business, 2014-2019
Gross Margin of Realcan Pharmaceutical by Business, 2014-2019
Revenue and Net Income of Shanghai Pharmaceuticals Holding, 2013-2019
Revenue Breakdown of Shanghai Pharmaceuticals Holding by Business, 2014-2019
Revenue Structure of Shanghai Pharmaceuticals Holding by Business, 2014-2019
Revenue Breakdown of Shanghai Pharmaceuticals Holding by Region, 2014-2019
Gross Margin of Shanghai Pharmaceuticals Holding by Business, 2014-2019
Revenue and Net Income of Zhejiang Int'l Group, 2013-2019
Revenue Breakdown of Zhejiang Int'l Group by Business, 2017-2019
Gross Margin of Zhejiang Int'l Group’s Pharmaceutical Sales Business, 2016-2019
Revenue and Net Income of Zhejiang Zhenyuan, 2013-2019
Revenue Breakdown of Zhejiang Zhenyuan by Business, 2014-2019
Revenue Structure of Zhejiang Zhenyuan by Business, 2014-2019
Gross Margin of Zhejiang Zhenyuan by Business, 2014-2019
Revenue and Net Income of China Meheco, 2013-2019
Revenue Breakdown of China Meheco by Business, 2014-2019
Revenue Structure of China Meheco by Business, 2014-2019
Gross Margin of China Meheco by Business, 2014-2019
Revenue and Net Income of Charmacy Pharmaceutical, 2013-2019
Revenue Breakdown of Charmacy Pharmaceutical by Product/Client, 2013-2019
Revenue Structure of Charmacy Pharmaceutical by Product/Client, 2013-2019
Gross Margin of Charmacy Pharmaceutical, 2013-2019
Luyan Pharma’s Investment Projects with Raised Funds by Initial Public Offerings
Revenue and Net Income of Luyan Pharma, 2013-2019
Revenue Breakdown of Luyan Pharma by Business, 2014-2019
Revenue Structure of Luyan Pharma by Business, 2014-2019
Gross Margin of Luyan Pharma’s Pharmaceutical Wholesale Business, 2014-2019
Revenue and Net Income of China Resources Pharmaceutical Group, 2013-2019
Revenue Breakdown of China Resources Pharmaceutical Group by Business, 2013-2019
Revenue Structure of China Resources Pharmaceutical Group by Business, 2013-2019
Gross Margin of China Resources Pharmaceutical Group, 2013-2019
Development Strategy of China Resources Pharmaceutical Commercial Group Co., Ltd., 2020
Revenue and Net Income of DaShenLin Pharmaceutical, 2014-2019
Revenue Breakdown of DaShenLin Pharmaceutical by Business, 2014-2018
Revenue Structure of DaShenLin Pharmaceutical by Business, 2014-2018
Gross Margin of DaShenLin Pharmaceutical, 2013-2018

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号